RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

Phase 1TerminatedNCT00060515

Repligen Corporation12 enrolled

Overview

The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Enrollment

Sex: ALLMin age: 3 Years

Medical Language ↔ Plain English

Mitochondrial Disease

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.